Eikon Therapeutics, Inc.’s (NASDAQ:EIKN) Lock-Up Period Set To Expire on August 4th

Eikon Therapeutics’ (NASDAQ:EIKN) lock-up period is set to expire on Tuesday, August 4th. Eikon Therapeutics had issued 21,177,600 shares in its IPO on February 5th. The total size of the offering was $381,196,800 based on an initial share price of $18.00. After the expiration of Eikon Therapeutics’ lock-up period, major shareholders and company insiders will be able to sell their shares of the company.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on EIKN shares. Weiss Ratings initiated coverage on shares of Eikon Therapeutics in a research note on Monday, June 1st. They set a “sell (e-)” rating on the stock. Wedbush decreased their target price on shares of Eikon Therapeutics from $7.00 to $5.00 and set an “underperform” rating for the company in a research report on Tuesday, May 12th. Wall Street Zen cut shares of Eikon Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, April 5th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Eikon Therapeutics in a research report on Tuesday, June 2nd. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, Eikon Therapeutics currently has an average rating of “Hold” and a consensus target price of $25.20.

Eikon Therapeutics Price Performance

EIKN opened at $9.01 on Thursday. The business has a 50 day moving average price of $10.19. The firm has a market capitalization of $487.79 million and a P/E ratio of -3.66. Eikon Therapeutics has a 1-year low of $7.90 and a 1-year high of $17.40.

Eikon Therapeutics (NASDAQ:EIKN) last issued its quarterly earnings results on Monday, March 30th. The company reported ($26.23) earnings per share (EPS) for the quarter.

About Eikon Therapeutics

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.